Eflornithine is under clinical development by Panbela Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eflornithine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eflornithine overview

Eflornithine hydrochloride (CPP-1X) is under development for the treatment of STK11 mutated non-small cell lung cancer, refractory or relapsed neuroblastoma, gastric cancer, pancreatic cancer, metastatic castrate resistant prostate cancer (mCRPC) and early onset type 1 diabetes mellitus. The drug candidate is administered through oral route in the form of tablet and high dose powder. CPP-1X acts by targeting ornithine decarboxylase. CPP-1X is a difluoromethylated ornithine (DFMO) compound that displays antiapoptotic, antiangiogenic and antiparasitic activity. It was also under development for the treatment of familial adenomatous polyposis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Panbela Therapeutics overview

Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.

For a complete picture of Eflornithine’s drug-specific PTSR and LoA scores, buy the report here.